Abstract 19 First part
First part
Background. Over the last decade, recombinant human granulocyte-colony stimulating factor (G-CSF) has had a major impact on management of "severe chronic neutropenia", a term used collectively that refers to congenital idiopathic, or cyclic neutropenia. More than 90% of patients respond to G-CSF with an increase in neutrophils to > 1.5 × 109/L, and with a marked reduction in infections and a vastly improved survival. Several reports indicate that responders with congenital neutropenia have developed myelodysplastic syndromes and acute myeloblastic leukemia (MDS/AML) raising the question on the role of G-CSF in the pathogenesis of the malignant transformation.
Methods. The Severe Chronic Neutropenia International Registry (SCNIR) has collected data on 531 neutropenic patients from 13 countries treated with G-CSF from 1987 to 1997, including 302 patients with congenital neutropenia. To clarify the risk of MDS/AML in congenital neutropenia and the potential role of G-CSF in pathogenesis, these data were analyzed with respect to treatment and patient demographics.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Freedman, M., Bonilla, M., Fier, C. et al. IMPROVED SURVIVAL FROM GRANULOCYTE-COLONY STIMULATING FACTOR THERAPY FOR CONGENITAL NEUTROPENIA UNMASKS PREDISPOSITION TO MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA. Pediatr Res 45, 942 (1999). https://doi.org/10.1203/00006450-199906000-00266
Issue Date:
DOI: https://doi.org/10.1203/00006450-199906000-00266